TP53 and neoplasm: Previous insights into the inhibition of the p53-MDM2/MDMX interaction also reveal that the most of the peptide and non-peptide inhibitors, such as Nutlins and MI-219, provide strong anti-tumor potential of MDM2 inhibitors, but they do not efficiently inhibit the interaction of MDMX with p53 [6,14–24].